Kaleido Biosciences, Inc (KLDO)

Etorro trading 970x250
Kaleido Biosciences, Inc (KLDO) Logo

About Kaleido Biosciences, Inc

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Address: 65 Hayden Avenue, Lexington, MA, United States, 02421

Kaleido Biosciences, Inc News and around…

Latest news about Kaleido Biosciences, Inc (KLDO) common stock and company :

Kaleido Biosciences Becomes Oversold (KLDO)
19 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
19 Oct, 2021 FinancialContent

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:INDP) from Hold to Buy. Indaptus Therapeutics ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
19 Oct, 2021 FinancialContent

Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market ...

Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
13 Oct, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.

Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit
12 Oct, 2021 Yahoo! Finance

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19. The webcast of the

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

36 Biggest Movers From Yesterday
06 Oct, 2021 FinancialContent

Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares climbed 36.4% to settle at $10.35 on Tuesday amid an increase in the price of ...

Why Did Kaleido Shares Plunge 10% On Tuesday?
05 Oct, 2021 FinancialContent

Kaleido Biosciences Inc(NASDAQ: KLDO)announced topline datafrom the non-IND/CTA clinical study evaluating KB295, a ...

Mid-Afternoon Market Update: Dow Jumps 450 Points; Comtech Telecommunications Shares Slide
05 Oct, 2021 FinancialContent

Toward the end of trading Tuesday, the Dow traded up 1.36% to 34,464.68 while the NASDAQ rose 1.68% to 14,494.86. The S&P also rose, ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
05 Oct, 2021 FinancialContent

Gainers Synaptogenix (NASDAQ:SNPX) stock increased by 19.72% to $10.5 during Tuesday's regular session. Trading volume for this ...

Mid-Day Market Update: Crude Oil Rises 2%; UpHealth Shares Plunge
05 Oct, 2021 Yahoo! Finance

Midway through trading Tuesday, the Dow traded up 1.25% to 34,429.02 while the NASDAQ rose 1.42% to 14,458.35. The S&P also rose, gaining 1.33% to 4,357.69. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 43,852,260 cases with around 703,280 deaths. India confirmed a total of at least 33,853,040 cases and 449,260 deaths, while Brazil reported over 21,478,540 COVID-19 cases with 598,150 deaths. In total, there were at least 235,472,580 cases of C

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis
05 Oct, 2021 Yahoo! Finance

KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal calprotectin, fecal lactoferrin, and FimH - observed at end of study Virtual R&D Presentation, highlighting the ulcerative colitis and chronic obstructive pulmonary disease programs, to be held today at 8:00 a.m. ET LEXINGTON, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: K

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
03 Oct, 2021 FinancialContent
Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021
29 Sep, 2021 FinancialContent
Kaleido Biosciences's Return On Capital Employed Insights
28 Sep, 2021 FinancialContent

Kaleido Biosciences (NASDAQ:KLDO) brought in sales totaling $211.00 thousand during Q2 according to data provided by Benzinga Pro. ...

Those who invested in Kaleido Biosciences (NASDAQ:KLDO) a year ago are up 12%
23 Sep, 2021 Yahoo! Finance

While Kaleido Biosciences, Inc. ( NASDAQ:KLDO ) shareholders are probably generally happy, the stock hasn't had...

Add Up The Pieces: BIB Could Be Worth $125
10 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $124.52 per unit.

FDA Questions Kaleido Biosciences 'Non-IND' COVID-19 Trial
07 Sep, 2021 FinancialContent

TheFDA has issued a warning lettertoKaleido Biosciences Inc(NASDAQ: KLDO), blasting its “failure to ...

Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference
02 Sep, 2021 FinancialContent
Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates
11 Aug, 2021 Yahoo! Finance

Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kaleido Biosciences Reports Second Quarter 2021 Financial Results
11 Aug, 2021 FinancialContent
Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial
10 Aug, 2021 FinancialContent

On track to initiate Phase 2 trial in the first quarter of 2022

Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors
09 Aug, 2021 FinancialContent

Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth Conference
06 Aug, 2021 FinancialContent
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

Analysts Anticipate FDM To Hit $74
29 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $74.44 per unit.

Kaleido Biosciences, Inc (KLDO) is a NASDAQ Common Stock listed in , ,

970x250